
<?phpxml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
>
<channel>
<title>World Pharma News / Published News</title>
<link>http://www.worldpharmanews.net</link>
<description>World Pharma News .net - Web 2.0 pharmaceutical news portal  votes</description>
<pubDate>Thu, 28 Aug 2008 00:04:54 CEST</pubDate>
<language>en</language>
<item>
<title><![CDATA[Study overturns century-old rule of pharmacology]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Study_overturns_century-old_rule_of_pharmacology/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Study_overturns_century-old_rule_of_pharmacology/</comments>
<pubDate>Thu, 28 Aug 2008 00:04:54 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Study_overturns_century-old_rule_of_pharmacology/</guid>
<description><![CDATA[One of pharmacology's oldest underlying principles looks set to be overturned. New findings from chemists at the UK's University of Warwick appear to contradict the century-old 'Overton's Rule',<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[ADAGIO trial results show Azilect slows progression of Parkinson's disease]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/ADAGIO_trial_results_show_Azilect%AE_slows_progression_of_Parkinsons_disease/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/ADAGIO_trial_results_show_Azilect%AE_slows_progression_of_Parkinsons_disease/</comments>
<pubDate>Thu, 28 Aug 2008 00:04:43 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/ADAGIO_trial_results_show_Azilect%AE_slows_progression_of_Parkinsons_disease/</guid>
<description><![CDATA[Lundbeck's partner Teva Pharmaceutical Industries Ltd. has announced that results of the phase III ADAGIO trial were presented during the 12th Congress of European Federation of Neurological Societi<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: August 2008: NuvaRing MDL Created In Federal Court System, Eastern District Of Missouri]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_August_2008_NuvaRing_MDL_Created_In_Federal_Court_System_Eastern_District_Of_Missouri/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_August_2008_NuvaRing_MDL_Created_In_Federal_Court_System_Eastern_District_Of_Missouri/</comments>
<pubDate>Wed, 27 Aug 2008 10:29:16 CEST</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_August_2008_NuvaRing_MDL_Created_In_Federal_Court_System_Eastern_District_Of_Missouri/</guid>
<description><![CDATA[Ruling By Judicial Panel on Multidistrict Litigation Will Result In Transfer Of All NuvaRing Federal Court Cases<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: FDA Warns Sandoz About Possible Quality-Control Problems At Its North Carolina Generic Drug Manufacturing Facility]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_FDA_Warns_Sandoz_About_Possible_Quality-Control_Problems_At_Its_North_Carolina_Generic_Drug_Manufacturing_Facility/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_FDA_Warns_Sandoz_About_Possible_Quality-Control_Problems_At_Its_North_Carolina_Generic_Drug_Manufacturing_Facility/</comments>
<pubDate>Wed, 27 Aug 2008 10:29:04 CEST</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_FDA_Warns_Sandoz_About_Possible_Quality-Control_Problems_At_Its_North_Carolina_Generic_Drug_Manufacturing_Facility/</guid>
<description><![CDATA[Inspection Found Sandoz Failed To Properly Validate Manufacturing Process For Metoprolol Succinate ER Tablets (Generic Form Of Toprol XL) Before Distributing Pills<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Brings complementary capabilities in India to address patient populations most at risk]]></title>
<link>http://www.worldpharmanews.net/Corporate/Brings_complementary_capabilities_in_India_to_address_patient_populations_most_at_risk/</link>
<comments>http://www.worldpharmanews.net/Corporate/Brings_complementary_capabilities_in_India_to_address_patient_populations_most_at_risk/</comments>
<pubDate>Wed, 27 Aug 2008 10:28:51 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Corporate</category>
<guid>http://www.worldpharmanews.net/Corporate/Brings_complementary_capabilities_in_India_to_address_patient_populations_most_at_risk/</guid>
<description><![CDATA[Genzyme Corp. (Nasdaq: GENZ), a global leader in biotechnology, and Medicines for Malaria Venture (MMV), a not-for-profit virtual research and development (R&amp;D) organization dedicated to reducing the<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Alpharma Responds To Unsolicited Proposal By King Pharmaceuticals, Inc.]]></title>
<link>http://www.worldpharmanews.net/Financial/Alpharma_Responds_To_Unsolicited_Proposal_By_King_Pharmaceuticals_Inc-/</link>
<comments>http://www.worldpharmanews.net/Financial/Alpharma_Responds_To_Unsolicited_Proposal_By_King_Pharmaceuticals_Inc-/</comments>
<pubDate>Tue, 26 Aug 2008 01:15:11 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Alpharma_Responds_To_Unsolicited_Proposal_By_King_Pharmaceuticals_Inc-/</guid>
<description><![CDATA[Alpharma, Inc. (NYSE: ALO), a global specialty pharmaceutical company, confirmed that it received an unsolicited, non-binding proposal from King Pharmaceuticals, Inc. (NYSE: KG) to acquire all of the<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[King Proposes Acquisition of Alpharma for $33 Per Share in Cash]]></title>
<link>http://www.worldpharmanews.net/Financial/King_Proposes_Acquisition_of_Alpharma_for_33_Per_Share_in_Cash/</link>
<comments>http://www.worldpharmanews.net/Financial/King_Proposes_Acquisition_of_Alpharma_for_33_Per_Share_in_Cash/</comments>
<pubDate>Mon, 25 Aug 2008 00:15:35 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/King_Proposes_Acquisition_of_Alpharma_for_33_Per_Share_in_Cash/</guid>
<description><![CDATA[King Pharmaceuticals, Inc. (NYSE: KG) announced that it has submitted to the Board of Directors of Alpharma Inc. (NYSE: ALO) a proposal to acquire all of the outstanding shares of common stock of Alp<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[FDA Approves First Bone Marrow Stimulator to Treat Immune-Related Low Platelet Counts]]></title>
<link>http://www.worldpharmanews.net/Product/FDA_Approves_First_Bone_Marrow_Stimulator_to_Treat_Immune-Related_Low_Platelet_Counts/</link>
<comments>http://www.worldpharmanews.net/Product/FDA_Approves_First_Bone_Marrow_Stimulator_to_Treat_Immune-Related_Low_Platelet_Counts/</comments>
<pubDate>Mon, 25 Aug 2008 00:14:56 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/FDA_Approves_First_Bone_Marrow_Stimulator_to_Treat_Immune-Related_Low_Platelet_Counts/</guid>
<description><![CDATA[The U.S. Food and Drug Administration approved Nplate (romiplostim), the first product that directly stimulates the bone marrow to produce needed platelets in patients with a rare blood disorder that<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: August 2008: FDA Issues Its Final Version Of A New Rule Which May Give Complete Immunity To Drug And Medical Device Companies]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_August_2008_FDA_Issues_Its_Final_Version_Of_A_New_Rule_Which_May_Give_Complete_Immunity_To_Drug_And_Medical_Device_Companies/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_August_2008_FDA_Issues_Its_Final_Version_Of_A_New_Rule_Which_May_Give_Complete_Immunity_To_Drug_And_Medical_Device_Companies/</comments>
<pubDate>Sun, 24 Aug 2008 11:59:06 CEST</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_August_2008_FDA_Issues_Its_Final_Version_Of_A_New_Rule_Which_May_Give_Complete_Immunity_To_Drug_And_Medical_Device_Companies/</guid>
<description><![CDATA[FDA Rule Could Serve To Defeat Lawsuits Alleging Failure To Warn About Potentially Harmful Effects Of Prescription Drugs And Medical Devices<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Manhattan Research's ePharma Physician study ranks the top online journals by physician visitation]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Manhattan_Researchs_ePharma_Physician%AE_study_ranks_the_top_online_journals_by_physician_visitation/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Manhattan_Researchs_ePharma_Physician%AE_study_ranks_the_top_online_journals_by_physician_visitation/</comments>
<pubDate>Sat, 23 Aug 2008 11:56:02 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Manhattan_Researchs_ePharma_Physician%AE_study_ranks_the_top_online_journals_by_physician_visitation/</guid>
<description><![CDATA[The New England Journal of Medicine and American Family Physician rank as top online medical journals among U.S. primary care physicians, according to the just released ePharma Physician® v8.0 study <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[New Trial to Evaluate Nexavar as Adjuvant Therapy in Liver Cancer]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/New_Trial_to_Evaluate_Nexavar%AE_as_Adjuvant_Therapy_in_Liver_Cancer/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/New_Trial_to_Evaluate_Nexavar%AE_as_Adjuvant_Therapy_in_Liver_Cancer/</comments>
<pubDate>Fri, 22 Aug 2008 00:04:13 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/New_Trial_to_Evaluate_Nexavar%AE_as_Adjuvant_Therapy_in_Liver_Cancer/</guid>
<description><![CDATA[Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. announced the start of a Phase III study with Nexavar® (sorafenib) tablets in liver cancer. The randomized, double-blind, placebo<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novo Nordisk joins the Call to Action for gender equality]]></title>
<link>http://www.worldpharmanews.net/Corporate/Novo_Nordisk_joins_the_Call_to_Action_for_gender_equality/</link>
<comments>http://www.worldpharmanews.net/Corporate/Novo_Nordisk_joins_the_Call_to_Action_for_gender_equality/</comments>
<pubDate>Fri, 22 Aug 2008 00:04:03 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Corporate</category>
<guid>http://www.worldpharmanews.net/Corporate/Novo_Nordisk_joins_the_Call_to_Action_for_gender_equality/</guid>
<description><![CDATA[Yesterday, the Danish Minister for Development Cooperation Ms Ulla Tørnæs handed over a torch to Executive Vice President Lise Kingo, Novo Nordisk, at a ceremony in Copenhagen. With the torch Ms Tørn<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[DAIICHI SANKYO continues its expansion in Germany and Europe]]></title>
<link>http://www.worldpharmanews.net/Corporate/DAIICHI_SANKYO_continues_its_expansion_in_Germany_and_Europe/</link>
<comments>http://www.worldpharmanews.net/Corporate/DAIICHI_SANKYO_continues_its_expansion_in_Germany_and_Europe/</comments>
<pubDate>Thu, 21 Aug 2008 20:02:38 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Corporate</category>
<guid>http://www.worldpharmanews.net/Corporate/DAIICHI_SANKYO_continues_its_expansion_in_Germany_and_Europe/</guid>
<description><![CDATA[At the beginning of August, DAIICHI SANKYO DEUTSCHLAND GmbH is planning to take over most of the sales force for primary-care physicians in Germany used by Merck Pharma GmbH and to integrate them int<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: Wyeth v. Levine Supreme Court Hearing On Federal Preemption Of Drug Injury Lawsuits]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Wyeth_v-_Levine_Supreme_Court_Hearing_On_Federal_Preemption_Of_Drug_Injury_Lawsuits/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Wyeth_v-_Levine_Supreme_Court_Hearing_On_Federal_Preemption_Of_Drug_Injury_Lawsuits/</comments>
<pubDate>Thu, 21 Aug 2008 00:04:08 CEST</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Wyeth_v-_Levine_Supreme_Court_Hearing_On_Federal_Preemption_Of_Drug_Injury_Lawsuits/</guid>
<description><![CDATA[Various Parties Have Filed Briefs With Their Arguments About Whether Or Not An Injured Patient Should Be Able To File A Lawsuit Against The Drug Company<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Industry Luminaries and Record Attendance Posted at 2008 Pharma CI Conference, September 15-17]]></title>
<link>http://www.worldpharmanews.net/Conferences_Events/Industry_Luminaries_and_Record_Attendance_Posted_at_2008_Pharma_CI_Conference_September_15-17/</link>
<comments>http://www.worldpharmanews.net/Conferences_Events/Industry_Luminaries_and_Record_Attendance_Posted_at_2008_Pharma_CI_Conference_September_15-17/</comments>
<pubDate>Thu, 21 Aug 2008 00:03:57 CEST</pubDate>
<dc:creator>ayueh</dc:creator>
<category>Conferences &amp; Events</category>
<guid>http://www.worldpharmanews.net/Conferences_Events/Industry_Luminaries_and_Record_Attendance_Posted_at_2008_Pharma_CI_Conference_September_15-17/</guid>
<description><![CDATA[Join the 200+ attendees already registered to attend.  Visit Pharma CI Conference (pharma competitive intelligence conference) at www.pharmaciconference.com and view the newly posted attendee list.<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance]]></title>
<link>http://www.worldpharmanews.net/Corporate/Bristol-Myers_Squibb_and_PDL_BioPharma_Enter_Global_Alliance/</link>
<comments>http://www.worldpharmanews.net/Corporate/Bristol-Myers_Squibb_and_PDL_BioPharma_Enter_Global_Alliance/</comments>
<pubDate>Thu, 21 Aug 2008 00:03:46 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Corporate</category>
<guid>http://www.worldpharmanews.net/Corporate/Bristol-Myers_Squibb_and_PDL_BioPharma_Enter_Global_Alliance/</guid>
<description><![CDATA[Bristol-Myers Squibb Company (NYSE: BMY) and PDL BioPharma, Inc. (NASDAQ: PDLI) announced an agreement for the global development and commercialization of PDL BioPharma's anti-CS1 antibody, elotuzum<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Nycomed - strong results in second quarter 2008]]></title>
<link>http://www.worldpharmanews.net/Financial/Nycomed_-_strong_results_in_second_quarter_2008/</link>
<comments>http://www.worldpharmanews.net/Financial/Nycomed_-_strong_results_in_second_quarter_2008/</comments>
<pubDate>Wed, 20 Aug 2008 00:06:36 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Nycomed_-_strong_results_in_second_quarter_2008/</guid>
<description><![CDATA[In the first six months of 2008, Nycomed's adjusted EBITDA increased by 4.9% to € 653.7 million compared to € 623.3 million in the first six months of 2007, benefiting from the cost decreasing effect<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: August 2008: Byetta Associated With Hemorrhagic Pancreatitis And Necrotizing Pancreatitis]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_August_2008_Byetta_Associated_With_Hemorrhagic_Pancreatitis_And_Necrotizing_Pancreatitis/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_August_2008_Byetta_Associated_With_Hemorrhagic_Pancreatitis_And_Necrotizing_Pancreatitis/</comments>
<pubDate>Tue, 19 Aug 2008 00:02:30 CEST</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_August_2008_Byetta_Associated_With_Hemorrhagic_Pancreatitis_And_Necrotizing_Pancreatitis/</guid>
<description><![CDATA[FDA Has Learned Of Six Such Cases Since October 2007 &quot;Dear Doctor&quot; Letter About Acute Pancreatitis In Patients Taking Byetta<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Jacob Fleming Group is proud to announce a Pharma Sales Week in Brussels]]></title>
<link>http://www.worldpharmanews.net/Conferences_Events/Jacob_Fleming_Group_is_proud_to_announce_a_Pharma_Sales_Week_in_Brussels/</link>
<comments>http://www.worldpharmanews.net/Conferences_Events/Jacob_Fleming_Group_is_proud_to_announce_a_Pharma_Sales_Week_in_Brussels/</comments>
<pubDate>Tue, 19 Aug 2008 00:02:17 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Conferences &amp; Events</category>
<guid>http://www.worldpharmanews.net/Conferences_Events/Jacob_Fleming_Group_is_proud_to_announce_a_Pharma_Sales_Week_in_Brussels/</guid>
<description><![CDATA[21-22 October, 2008 - Pharma Sales Training &amp; Development Conference. 23-24 October, 2008 - Pharma Sales Technology &amp; Customer Excellence. Successful Pharma companies understand, how to effectively e<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[AstraZeneca Gives FluMist A Shot In The Arm - CNBC.com]]></title>
<link>http://www.worldpharmanews.net/Blogs/AstraZeneca_Gives_FluMist_A_Shot_In_The_Arm_-_CNBC-com/</link>
<comments>http://www.worldpharmanews.net/Blogs/AstraZeneca_Gives_FluMist_A_Shot_In_The_Arm_-_CNBC-com/</comments>
<pubDate>Tue, 19 Aug 2008 00:02:05 CEST</pubDate>
<dc:creator>G00gle</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/AstraZeneca_Gives_FluMist_A_Shot_In_The_Arm_-_CNBC-com/</guid>
<description><![CDATA[Ads for flu vaccines have traditionally been confined to public service announcements (PSAs), health and media alerts. So, that's why I was surprised to see this colorful full-page ad in The New Yor<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Fraunhofer Life Science Symposium, Leipzig, Germany]]></title>
<link>http://www.worldpharmanews.net/Conferences_Events/Fraunhofer_Life_Science_Symposium_Leipzig_Germany/</link>
<comments>http://www.worldpharmanews.net/Conferences_Events/Fraunhofer_Life_Science_Symposium_Leipzig_Germany/</comments>
<pubDate>Mon, 18 Aug 2008 17:52:02 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Conferences &amp; Events</category>
<guid>http://www.worldpharmanews.net/Conferences_Events/Fraunhofer_Life_Science_Symposium_Leipzig_Germany/</guid>
<description><![CDATA[The Fraunhofer Institute for Cell Therapy and Immunology will hold the third Life Science Symposium in Leipzig, Germany, on 24 and 25 October. This time, the symposium will be dedicated to ischaemia <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Divestment of four Roche pharmaceutical products to Meda]]></title>
<link>http://www.worldpharmanews.net/Financial/Divestment_of_four_Roche_pharmaceutical_products_to_Meda/</link>
<comments>http://www.worldpharmanews.net/Financial/Divestment_of_four_Roche_pharmaceutical_products_to_Meda/</comments>
<pubDate>Mon, 18 Aug 2008 10:31:14 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Divestment_of_four_Roche_pharmaceutical_products_to_Meda/</guid>
<description><![CDATA[Roche and Meda, an international specialty pharmaceutical company based in Solna (Stockholm), Sweden, have signed an agreement for the sale of four Roche pharmaceutical products to Meda. The world wi<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Abcam and Transinsight Collaborate in the Area of Semantic Search Technologies]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Abcam_and_Transinsight_Collaborate_in_the_Area_of_Semantic_Search_Technologies/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Abcam_and_Transinsight_Collaborate_in_the_Area_of_Semantic_Search_Technologies/</comments>
<pubDate>Sat, 16 Aug 2008 11:23:27 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Abcam_and_Transinsight_Collaborate_in_the_Area_of_Semantic_Search_Technologies/</guid>
<description><![CDATA[Abcam, a bioscience company specialising in the supply of antibodies from a web-based catalogue and Transinsight, a specialist in semantic search technologies announced a collaboration in the field o<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: 655 Fosamax Lawsuits Have Been Filed Against Merck &amp; Co. According To June 30, 2008 Update]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_655_Fosamax_Lawsuits_Have_Been_Filed_Against_Merck__Co-_According_To_June_30_2008_Update/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_655_Fosamax_Lawsuits_Have_Been_Filed_Against_Merck__Co-_According_To_June_30_2008_Update/</comments>
<pubDate>Fri, 15 Aug 2008 00:15:47 CEST</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_655_Fosamax_Lawsuits_Have_Been_Filed_Against_Merck__Co-_According_To_June_30_2008_Update/</guid>
<description><![CDATA[Most Of These Product Liability Cases Allege Fosamax Caused Drug-Induced Osteonecrosis Of The Jaw (ONJ)<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[AstraZeneca and Abbott Expand Relationship to Include Co-Promotion of CRESTOR]]></title>
<link>http://www.worldpharmanews.net/Product/AstraZeneca_and_Abbott_Expand_Relationship_to_Include_Co-Promotion_of_CRESTOR%AE/</link>
<comments>http://www.worldpharmanews.net/Product/AstraZeneca_and_Abbott_Expand_Relationship_to_Include_Co-Promotion_of_CRESTOR%AE/</comments>
<pubDate>Fri, 15 Aug 2008 00:15:34 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/AstraZeneca_and_Abbott_Expand_Relationship_to_Include_Co-Promotion_of_CRESTOR%AE/</guid>
<description><![CDATA[AstraZeneca and Abbott announced today that they have entered into an agreement for Abbott to promote AstraZeneca's CRESTOR® (rosuvastatin calcium), a medication used along with diet to reduce high<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Physicians Expect to Shift More Time to Online Professional Resources in the Coming Years]]></title>
<link>http://www.worldpharmanews.net/Research_Development/Physicians_Expect_to_Shift_More_Time_to_Online_Professional_Resources_in_the_Coming_Years/</link>
<comments>http://www.worldpharmanews.net/Research_Development/Physicians_Expect_to_Shift_More_Time_to_Online_Professional_Resources_in_the_Coming_Years/</comments>
<pubDate>Fri, 15 Aug 2008 00:15:22 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/Physicians_Expect_to_Shift_More_Time_to_Online_Professional_Resources_in_the_Coming_Years/</guid>
<description><![CDATA[Physicians report that they will shift a significant amount of time currently devoted to offline professional sources to their online counterparts in the coming years, according to the just released <br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Teva Reports Second Quarter 2008 Results - Record Quarterly Sales of $2,823 Million]]></title>
<link>http://www.worldpharmanews.net/Financial/Teva_Reports_Second_Quarter_2008_Results_-_Record_Quarterly_Sales_of_2823_Million/</link>
<comments>http://www.worldpharmanews.net/Financial/Teva_Reports_Second_Quarter_2008_Results_-_Record_Quarterly_Sales_of_2823_Million/</comments>
<pubDate>Thu, 14 Aug 2008 09:57:07 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Teva_Reports_Second_Quarter_2008_Results_-_Record_Quarterly_Sales_of_2823_Million/</guid>
<description><![CDATA[Net sales for the second quarter of 2008 increased 18 percent to $2,823 million, compared to $2,386 million in the second quarter of 2007. Net income for the second quarter of 2008 totaled $539 milli<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: Senators Kennedy And Leahy Introduce Legislation To Protect Patients From Dangerous And Defective Devices]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Senators_Kennedy_And_Leahy_Introduce_Legislation_To_Protect_Patients_From_Dangerous_And_Defective_Devices/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Senators_Kennedy_And_Leahy_Introduce_Legislation_To_Protect_Patients_From_Dangerous_And_Defective_Devices/</comments>
<pubDate>Wed, 13 Aug 2008 00:16:42 CEST</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_Senators_Kennedy_And_Leahy_Introduce_Legislation_To_Protect_Patients_From_Dangerous_And_Defective_Devices/</guid>
<description><![CDATA[August 2008 Counterpart of HR 6381, Medical Device Safety Act 2008, Which Was Sponsored By Congressmen Waxman And Pallone<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[IAFF Launches Smoking Cessation Campaign with Pfizer]]></title>
<link>http://www.worldpharmanews.net/Corporate/IAFF_Launches_Smoking_Cessation_Campaign_with_Pfizer/</link>
<comments>http://www.worldpharmanews.net/Corporate/IAFF_Launches_Smoking_Cessation_Campaign_with_Pfizer/</comments>
<pubDate>Wed, 13 Aug 2008 00:16:23 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Corporate</category>
<guid>http://www.worldpharmanews.net/Corporate/IAFF_Launches_Smoking_Cessation_Campaign_with_Pfizer/</guid>
<description><![CDATA[The International Association of Fire Fighters has announced the launch of a new initiative to help fire fighters, family members and friends to quit smoking cigarettes. &quot;Our goal is to help make th<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[European researchers advance bone implants technology]]></title>
<link>http://www.worldpharmanews.net/Research_Development/European_researchers_advance_bone_implants_technology/</link>
<comments>http://www.worldpharmanews.net/Research_Development/European_researchers_advance_bone_implants_technology/</comments>
<pubDate>Wed, 13 Aug 2008 00:16:13 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Research &amp; Development</category>
<guid>http://www.worldpharmanews.net/Research_Development/European_researchers_advance_bone_implants_technology/</guid>
<description><![CDATA[European researchers are relentless in their pursuit to develop technologies across the board. Case in point is medical technology and bone implants. Enter a team of researchers from the Germany-base<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Boehringer Ingelheim continued to post strong growth in local currencies in the first half of 2008]]></title>
<link>http://www.worldpharmanews.net/Financial/Boehringer_Ingelheim_continued_to_post_strong_growth_in_local_currencies_in_the_first_half_of_2008/</link>
<comments>http://www.worldpharmanews.net/Financial/Boehringer_Ingelheim_continued_to_post_strong_growth_in_local_currencies_in_the_first_half_of_2008/</comments>
<pubDate>Tue, 12 Aug 2008 08:37:56 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Boehringer_Ingelheim_continued_to_post_strong_growth_in_local_currencies_in_the_first_half_of_2008/</guid>
<description><![CDATA[The pharmaceutical company Boehringer Ingelheim continued to post strong growth in local currencies in the first half of 2008 (+9.0%). On account of the strength of the euro against the US dollar and<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Grindeks profit reaches 5 million lats in the first half of 2008]]></title>
<link>http://www.worldpharmanews.net/Financial/Grindeks_profit_reaches_5_million_lats_in_the_first_half_of_2008/</link>
<comments>http://www.worldpharmanews.net/Financial/Grindeks_profit_reaches_5_million_lats_in_the_first_half_of_2008/</comments>
<pubDate>Mon, 11 Aug 2008 00:08:49 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Grindeks_profit_reaches_5_million_lats_in_the_first_half_of_2008/</guid>
<description><![CDATA[The financial statements of the JSC Grindeks for the first half of the year 2008, submitted to Riga Stock Exchange, certify that the Group of Grindeks has operated successfully during the first six m<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: July 2008 Journal Article: Bextra And Vioxx Increase Risk Of Cerebrovascular Events, Or Strokes]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_July_2008_Journal_Article_Bextra_And_Vioxx_Increase_Risk_Of_Cerebrovascular_Events_Or_Strokes/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_July_2008_Journal_Article_Bextra_And_Vioxx_Increase_Risk_Of_Cerebrovascular_Events_Or_Strokes/</comments>
<pubDate>Sun, 10 Aug 2008 12:18:42 CEST</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_July_2008_Journal_Article_Bextra_And_Vioxx_Increase_Risk_Of_Cerebrovascular_Events_Or_Strokes/</guid>
<description><![CDATA[Study Published In Stroke Shows Risk Not Increased With Celebrex Nor With Other Medications In NSAIDs Class Of Drugs<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[PLIVA Announces H1 2008 Results]]></title>
<link>http://www.worldpharmanews.net/Financial/PLIVA_Announces_H1_2008_Results/</link>
<comments>http://www.worldpharmanews.net/Financial/PLIVA_Announces_H1_2008_Results/</comments>
<pubDate>Sat, 09 Aug 2008 09:35:08 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/PLIVA_Announces_H1_2008_Results/</guid>
<description><![CDATA[PLIVA d.d. (ZSE: PLVA-R-A), a subsidiary of Barr Pharmaceuticals, Inc. (&quot;Barr&quot;), today reported financial results for the six month period ended 30 June 2008, prepared in accordance with Internatio<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Nycomed's preclinical anti-cancer program sold to Bayer Schering Pharma]]></title>
<link>http://www.worldpharmanews.net/Financial/Nycomeds_preclinical_anti-cancer_program_sold_to_Bayer_Schering_Pharma/</link>
<comments>http://www.worldpharmanews.net/Financial/Nycomeds_preclinical_anti-cancer_program_sold_to_Bayer_Schering_Pharma/</comments>
<pubDate>Fri, 08 Aug 2008 20:13:19 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Financial</category>
<guid>http://www.worldpharmanews.net/Financial/Nycomeds_preclinical_anti-cancer_program_sold_to_Bayer_Schering_Pharma/</guid>
<description><![CDATA[Nycomed agreed with Bayer Schering Pharma on the sale of the preclinical anti-cancer program. The agreement is part of Nycomed's strategic decision not to further invest in oncology R&amp;D activities. <br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Lipitor 80 mg Reduced the Risk of Heart Attack and Stroke]]></title>
<link>http://www.worldpharmanews.net/Product/Lipitor_80_mg_Reduced_the_Risk_of_Heart_Attack_and_Stroke/</link>
<comments>http://www.worldpharmanews.net/Product/Lipitor_80_mg_Reduced_the_Risk_of_Heart_Attack_and_Stroke/</comments>
<pubDate>Fri, 08 Aug 2008 08:24:14 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Product</category>
<guid>http://www.worldpharmanews.net/Product/Lipitor_80_mg_Reduced_the_Risk_of_Heart_Attack_and_Stroke/</guid>
<description><![CDATA[Pfizer Inc announced that, in patients with heart disease, type 2 diabetes and chronic kidney disease, Lipitor® (atorvastatin calcium) 80 mg significantly reduced the risk of major cardiovascular eve<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novartis Contractor Ran a Prostitution Ring from Work]]></title>
<link>http://www.worldpharmanews.net/Blogs/Novartis_Contractor_Ran_a_Prostitution_Ring_from_Work/</link>
<comments>http://www.worldpharmanews.net/Blogs/Novartis_Contractor_Ran_a_Prostitution_Ring_from_Work/</comments>
<pubDate>Thu, 07 Aug 2008 09:31:13 CEST</pubDate>
<dc:creator>cliffmz</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Novartis_Contractor_Ran_a_Prostitution_Ring_from_Work/</guid>
<description><![CDATA[A contractor who worked for Novartis was charged with running a prostitution ring from his desk at the drug maker's facility in Hanover, NJ. Luckily (for Novartis anyway) the actual 'services' were p<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Drug Injury Watch: More Serious Side Effect Warnings And Recalls Predicted Due To Current FDA Approval System]]></title>
<link>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_More_Serious_Side_Effect_Warnings_And_Recalls_Predicted_Due_To_Current_FDA_Approval_System/</link>
<comments>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_More_Serious_Side_Effect_Warnings_And_Recalls_Predicted_Due_To_Current_FDA_Approval_System/</comments>
<pubDate>Thu, 07 Aug 2008 09:30:57 CEST</pubDate>
<dc:creator>tjlpa</dc:creator>
<category>Blogs</category>
<guid>http://www.worldpharmanews.net/Blogs/Drug_Injury_Watch_More_Serious_Side_Effect_Warnings_And_Recalls_Predicted_Due_To_Current_FDA_Approval_System/</guid>
<description><![CDATA[August 2008 ASA Meeting: Sociologist Donald Light Presents His Paper, &quot;Institutional Foundations of the Vioxx Disaster&quot;<br/><br/>2 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Closure of the tipranavir trials SPRING and TICINO]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/Closure_of_the_tipranavir_trials_SPRING_and_TICINO/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/Closure_of_the_tipranavir_trials_SPRING_and_TICINO/</comments>
<pubDate>Thu, 07 Aug 2008 09:30:45 CEST</pubDate>
<dc:creator>god</dc:creator>
<category>Clinical Trials</category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/Closure_of_the_tipranavir_trials_SPRING_and_TICINO/</guid>
<description><![CDATA[After careful consideration of the feasibility of meeting the enrolment targets for the SPRING (Safety, efficacy and pharmacokinetics of tipranavir boosted with low dose ritonavir (500mg/200mg) twice<br/><br/>1 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[eyeforpharma's 3rd annual eCommunication and Online Marketing Conference]]></title>
<link>http://www.worldpharmanews.net/Conferences_Events/eyeforpharmas_3rd_annual_eCommunication_and_Online_Marketing_Conference/</link>
<comments>http://www.worldpharmanews.net/Conferences_Events/eyeforpharmas_3rd_annual_eCommunication_and_Online_Marketing_Conference/</comments>
<pubDate>Wed, 06 Aug 2008 09:47:38 CEST</pubDate>
<dc:creator>worldpharmanews</dc:creator>
<category>Conferences &amp; Events</category>
<guid>http://www.worldpharmanews.net/Conferences_Events/eyeforpharmas_3rd_annual_eCommunication_and_Online_Marketing_Conference/</guid>
<description><![CDATA[Challenges and opportunities for today's pharmaceutical e-marketers abound. From social networking tools and advanced physician portals to streaming video and closed loop strategies, the opportuniti<br/><br/>1 Vote(s) ]]></description>
</item>

</channel>
</rss>
